30 Day Trial

Smaller Diameter VCF Products Support Osseon's Revenue Growth


Osseon, developer of products to treat vertebral compression fractures, expects to post double-digit revenue growth for 4Q15, continuing a trend from the past two quarters.

A significant portion of growth is attributed to sales of smaller diameter products for vertebral compression treatment, which were launched in 4Q14. Osseon received FDA 510(k) clearance to market a 2ml steerable balloon for treatment of smaller vertebra in the thoracic and lumbar spine in 2Q14.

As of 4Q15, the company’s vertebral augmentation devices are available in multiple gauge sizes, including steerable needles and balloons, straight balloons, vertebral access systems, hand drills and other devices for VCF treatment. 

Company leadership also notes that Osseon’s steerable systems have been accepted by a number of GPOs and regional hospitals.

Source: Osseon LLC